With increasing time since diagnosis, only the severe infections continued to cause symptoms.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The neuraminidase inhibitor laninamivir, made by Biota Pharmaceuticals Inc. of Alpharetta, Ga., failed to perform better than a placebo at alleviating influenza symptoms in a phase 2 trial, the company said in a press release today, adding that it will no longer develop the drug.
An analysis of seven children infected with H7N9 avian influenza during the outbreak's second wave in China found that the illnesses were mild, a phenomenon that could contribute to spread of the virus. Researchers from China's Guangdong province published their findings today in an early online edition of the Pediatric Infectious Disease Journal.
Only 16% of flu patients received antivirals, while 30% received antibiotics.
Their consensus statement calls for better tools to weigh risks and benefits.
Canada's only flu vaccine plant, owned by London-based GSK, must respond within 30 days to unspecified problems identified by Health Canada inspectors at the Quebec City facility, according to a Canadian Press report yesterday.
Health Canada requested a plan and timeline for resolving the issues noted in the inspection report, which it presented to GSK on Jul 3.
Global flu activity remains at low levels, with slight increases in China and South America, the World Health Organization (WHO) said in its weekly update yesterday.
The agency said influenza activity remained at low levels in North America, Europe, northern Africa, and western Asia. Flu activity continues to decline in southern and southeastern Asia, as well, except for Singapore, which noted an increase.
An outbreak of an unknown febrile illness that initially prompted suspicion for hemorrhagic fever or Middle East respiratory syndrome coronavirus (MERS-CoV) has been diagnosed as dengue fever, the World Health Organization (WHO) said yesterday in a statement.
Health officials in China's Guangdong province today reported a fatal H7N9 avian influenza infection in a 42-year-old man, according to a health department statement translated and posted by FluTrackers, an infectious disease news message board.
Avian influenza viruses with components similar to those in the 1918 pandemic flu virus still circulate in nature, and genetic engineering experiments suggest it would take only a few mutations to turn them into a human threat, according to a team of scientists led by Yoshiro Kawaoka, DVM, PhD, of the University of Wisconsin.
Most Northern Hemisphere countries are at or approaching interseasonal flu levels, with North America and eastern Asia still reporting some influenza B circulation, the World Health Organization (WHO) said in its latest global flu update.
The countries at interseasonal levels included China, with the percentage of positive flu tests low in both the northern and southern parts of the country.
